

Cardiac arrhythmia monitoring after stroke

Matthias Endres

Klinik für Neurologie – Charité Universitätsmedizin Berlin
Centrum für Schlaganfallforschung Berlin

Acknowledgements


Funding from DFG under Germany's Excellence Strategy
– EXC-2049 – 390688087, BMBF, DZNE, DZHK, EU,
Corona Foundation, and Fondation Leducq

Conflicts of interest

Grants from Bayer and fees paid to the Charité from
AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi
Sankyo, Amgen, GSK, Sanofi, Covidien, Novartis, Pfizer.

- Atrial fibrillation: importance for secondary prevention
- Monitoring: how long ? Differences between stroke subtypes?
- Cryptogenic stroke/ESUS
 - *„Treat to Target“*
 - *„Fire and Forget“*
- Risk markers for Afib
 - Role of SVEA, P-wave indices, etc.
 - Biomarkers
- The „hen and egg“ question
 - Did Afib cause the stroke or vice versa?

“The more I look the more I find”



Haeusler et al. *Current Neurology & Neuroscience Reports* 2018 (modified)